Eligibility criteria
Condition
Infection
Sex
Females and Males
Age
18 + years
Inclusion criteria
Show details
Exclusion criteria
Show details
You are here
A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli
NCT00724919
Last updated on November 13, 2019
About this Study
To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, post- intervention in the selected medical centres
NCT00724919
Pfizer
Completed
A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Based on your search, you may also be interested in
Gram-negative Bacterial Infection
NCT04126031
All Genders
0+
Years
Multiple Sites
Respiratory Tract Infection
NCT04032093
Females
18+
Years
Multiple Sites
Serious Bacterial Infection
NCT03580044
All Genders
18+
Years
Multiple Sites
Respiratory Tract Infection
NCT04071158
Females
18+
Years
Multiple Sites
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title | A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli | |||
| Official Title | Association of Antibiotic Utilization Measures and Control of Extended-Spectrum ?-Lactamases (ESBLs) (A Post-Intervention Surveillance Study) | |||
| Brief Summary | To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, post- intervention in the selected medical centres | |||
| Detailed Description | This is post-interventional study to follow the acquisition rate of ESBP producing E. coli or K. pneumoniae at the sites involved in a previous interventional study. | |||
| Study Type | Observational | |||
| Study Design | Observational Model: Cohort Time Perspective: Prospective | |||
| Target Follow-Up Duration | Not Provided | |||
| Biospecimen | Not Provided | |||
| Sampling Method | Non-Probability Sample | |||
| Study Population | patients admitted to ICU/burn unit | |||
| Condition | Infection | |||
| Intervention | Not Provided | |||
| Study Groups/Cohorts | 1 | |||
| Publications * | Not Provided | |||
| * Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status | Completed | |||
| Actual Enrollment | 256 | |||
| Original Actual Enrollment | Same as current | |||
| Actual Study Completion Date | April 2004 | |||
| Actual Primary Completion Date | April 2004 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria | Inclusion
Patients were excluded if they had underlying conditions or diseases that were ultimately fatal within 48 hours | |||
| Sex/Gender |
| |||
| Ages | 18 Years and older (Adult, Older Adult) | |||
| Accepts Healthy Volunteers | No | |||
| Contacts | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries | Taiwan | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number | NCT00724919 | |||
| Other Study ID Numbers | 0910X-101440 | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement | Not Provided | |||
| Responsible Party | Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth | |||
| Study Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer | |||
| Collaborators | Not Provided | |||
| Investigators |
| |||
| PRS Account | Wyeth is now a wholly owned subsidiary of Pfizer | |||
| Verification Date | August 2008 | |||
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
BY PHONE
Pfizer Clinical Trials Contact Center
1-800-718-1021